Dupilumab Provides Sustained Relief From Prurigo Nodularis

Published Date: 28 Jul 2026

Dupilumab demonstrates sustained effectiveness and safety over 52 weeks in patients with prurigo nodularis in a real-world study.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

More men with prostate cancer are avoiding unnecessary surgery

2.

Even when they are not paying attention, children are still learning.

3.

FDA Approves New Bladder Cancer First-Line Standard of Care.

4.

"A lot" of aspirin reduces the risk of ovarian cancer, regardless of genetic factors, according to the JAMA study.

5.

AI is useful in low-resource areas for triaging breast masses.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot